The activity will discuss recent advances in the understanding of inhibitors in patients with hemophilia A, including the risks associated with inhibitors as well as current and new approaches to management.
Aptevo Therapeutics recently announced patient-reported data on individuals currently being treated with IXINITY®, the company’s recombinant factor IX product.
CSL Behring Discontinues Production and Distribution of Monoclate-P®
The study focused on disparities associated with bleeding symptoms, age at diagnosis and provider interventions for females with bleeding disorders.
Runners in the NYC Half Marathon are an inspiration to the bleeding disorders community.
The submission was based on positive results from a multi-stage clinical trial program which included more than 250 children and adults with hemophilia A worldwide
If you or someone you care for had contact with an HTC in 2017, your feedback is needed!
The goal of the workshop is to solicit hemophilia community-wide input into a coordinated national blueprint for future basic, translational, and clinical research.
The study focused on individuals who were previously treated prophylactically with a standard half-life (SHL) factor product, then switched to prophylaxis with an EHL therapy.
Steven Pipe, MD, NHF's Chair of MASAC, looks at the future of bleeding disorders treatment.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car